Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and has built collaborations with pioneers and leaders in the space. Our long-term vision is to create a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies for the bottom 99 % of the population globally.

We have embedded manufacturing and quality processes in the platform which will enable us to create a virtuous cycle of innovation and decrease the time to market for such therapies. Our lead product out of the platform is Eyecyte-RPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. Pivotal efficacy and safety studies for this product have started at Oregon Health and Science University and we expect to begin first in man studies for the same in 2022.

Enroll in our Global Research Alliance

Recent Scientific Papers

Konala VBR, Nandakumar S, Surendran…

Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies.

 Toxicol Appl Pharmacol. 2021;433:115792.

Nandakumar S, Shahani P, Datta…

Interventional Strategies for Parkinson Disease: Can Neural Precursor Cells Forge a Path Ahead?

 ACS Chem Neurosci. 2021;12(20):3785-3794.

Pal R

A small-molecule cocktail that beats cellular stress.

 Nat Methods. 2021;18(5):457-458

Konala VBR, Nandakumar S, Surendran…

Derivation of Induced Pluripotent Stem Cell (iPSC) Lines from Patient-Specific Peripheral Blood Mononuclear Cells (PBMC) Using Episomal Vectors.

 Methods Mol Biol. 2021 (Online ahead of print)

Battu R, Mallipatna A, Elackatt NJ, Schouten JSAG,

Webers Challenges of managing retinal dystrophies: an experience from south India. Ophthalmic Genetics.

2018. 39(1): 1-3.

Surendran H, Rathod RR. Pal R.

Generation of transplantable Retinal Pigmented Epithelial (RPE) cells for treatment of Age-related Macular Degeneration (AMD

2018. Meth Mol Biol. (Accepted).

Battu R, Mohan A, Khanna A, Kumar A, Shetty R

Retinal oxygen saturation in Retinitis Pigmentosa and macular dystrophies in Asian Indian eyes. Invest Ophthalmol Vis Sci. 2015.

56(5): 2798-802.

Battu R, Khanna A, Hegde B, Berendschot TT, Grover G, Schouten JS.

Correlation of Structure and Function of the Macula in patients with Retinitis Pigmentosa. Eye (Lond).

2015. 29(7): 895-901.
View all Scientific Papers

EyestemFollow

Eyestem
Retweet on TwitterEyestem Retweeted
Rajarshi Pal@RajarshiPal16·
30 Apr

In RCS rats and RD1 mice respectively…..Thanks for the opportunity to present! @jogin_desai @EyestemResearch @fightblindness @CaseyEye https://twitter.com/fightblindness/status/1520171599131037698

Twitter 1520244710702743553
Eyestem@EyestemResearch·
28 Apr

Eyestem is presenting today at the seventh annual Retinal cell/gene therapy innovation summit organized by @fightblindness and @CaseyEye . Do hear our Co-Founder @RajarshiPal16 on how our novel protocol demonstrated vision rescue in pre-clinical models. https://give.fightingblindness.org/event/retinal-cell-and-gene-therapy-innovation-summit-2022/e366552

Twitter 1519509524457361408

Career Openings

Research Associate

Project: Hands-on experience in gene editing tools like ZFN, TALEN, CRISPR/Cas9 preferred

Junior / Senior Research Fellow

Project: Hands-on experience in mammalian cell and tissue culture (preferably with stem or progenitor cells) and basic cell biology techniques

View all